Delivery Order SPE2DB22D9367-SPE2DB26FSU84
- Not listed
- The Defense Logistics Agency awarded a $36,976.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at...
- The Defense Logistics Agency awarded a delivery order valued at $36,976.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. This firm fixed-price delivery order, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a discrete pharmaceutical fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA....
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $55,464.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $36,758.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued on September 29, 2025, covers the supply of Trikafta 100-50-75 mg/150 mg tablets in quantities of 84 units, with a completion date of September 30, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $36,976.24 by the Defense Logistics Agency (DLA) on July 31, 2025, with an ultimate completion date of August 1, 2025. The delivery order, issued under a firm fixed-price contract structure with no set-aside designation, covers the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). Performance will occur at the contractor's...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $36,976.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, under a firm fixed-price contract type with no set-aside designation. This delivery order represents a discrete purchase from DMS...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $18,488.12 by the Defense Logistics Agency (DLA) on July 14, 2025. The delivery order, which is scheduled for completion by July 15, 2025, covers the supply of Trikafta 100-50-75 mg/150 mg tablets in a quantity of 84 units. This award was issued without set-aside designation and represents a single delivery order under DMS...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $36,948.04 to DMS Pharmaceutical Group Inc. for Trikafta 50-25-37.5 mg/75 mg pharmaceutical product (84 units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order carries an ultimate completion date of May 12, 2025, and represents performance at the vendor's Park Ridge facility. This...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $55,464.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and does not utilize a set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award Indefinite...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB26FSU84Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,976.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on October 27, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide. DMS Pharmaceutical Group serves as a critical regional prime vendor contractor under the PPV-G GEN V program, which authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables. The company's IDC, designated SPE2DR and valued at $499,999,999, extends through December 31, 2036, with a 30-month base period and three optional 30-month renewal periods. This delivery order for Trikafta, a specialty pharmaceutical used in cystic fibrosis treatment, reflects DMS Pharmaceutical Group's established role as a reliable supplier of specialty and branded medications supporting Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.0k | 10/27/25 |